BRKRP Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- LABORATORY ANALYTICAL INSTRUMENTS (3826) · industry map
- Exchange
- XNAS
- Employees
- 11,085
- List Date
- 2025-09-09
- CIK
- 0001109354
- Headquarters
- Billerica, MA
- Homepage
- https://www.bruker.com
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | -6.14% | -6.14% |
| Feb | -- | -8.53% | -8.53% |
| Mar | -- | -9.23% | -9.23% |
| Apr | -- | 1.97% | 1.97% |
| May | -- | 49.09% | 49.09% |
| Jun | -- | 3.04% | 3.04% |
| Jul | -- | 2.37% | 2.37% |
| Aug | -- | -9.69% | -9.69% |
| Sep | 3.54% | 13.47% | 8.51% |
| Oct | 11.12% | -5.96%* | 2.58% |
| Nov | 20.81% | -- | 20.81% |
| Dec | -0.34% | -- | -0.34% |
| Total | 38.52% | 20.43% | 29.48% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: BRKRP
Executive Summary
BULLISH (Confidence Level: 8/10)
Key drivers: Technical momentum signals, positive news sentiment Primary risks: High volatility, negative earnings surprises Investment thesis: BRKRP is a high-growth stock with strong technical momentum, supported by positive news sentiment and recent product launches. However, the stock's high volatility and potential for negative earnings surprises pose significant risks.
Recent news sentiment impact: The positive news headline about omics-based clinical trials research has contributed to the stock's recent rally, while the negative headlines from JPMorgan and The Motley Fool have been neutralized by the overall positive market environment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral; Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $376.89
- Middle Bollinger Band: $325.82
- Lower Bollinger Band: $274.76
Momentum Signals:
- RSI: 69.14 (neutral)
- MACD: Bullish, with a strong signal line crossover above the zero line
- Stochastic %K and %D: Overbought, indicating potential for a pullback
Volume Analysis: Volume SMA 20 is trending downwards, indicating decreasing institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: The majority of recent news headlines are positive, highlighting the company's growth prospects in the clinical trials research space. The negative headlines from JPMorgan and The Motley Fool have been overshadowed by the overall positive market environment.
Sentiment Assessment: Positive (60%) - Negative (20%) - Neutral (20%)
Catalyst Identification: Upcoming earnings release, potential product launches, and FDA approvals
Market Narrative: The news headlines align with the stock's recent price movement, supporting the bullish technical momentum signals. However, the high volatility poses a significant risk to the stock's future performance.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock relative to the market (beta >1.5)
Volatility Regime: Current volatility is above historical levels
Options Market Signals:
- IV rank: 0.45
- Put/call ratios: Neutral
- Unusual activity: None detected
Downside Protection: Support level at $325.82, risk management considerations suggest a stop-loss below this level.
Market Context & Positioning
Sector Performance: The stock is outperforming its sector and market averages
Institutional Activity: Volume patterns suggest decreasing institutional interest
Correlation Analysis: R-squared interpretation indicates high correlation with the broader market
Relative Valuation: The stock is trading within a neutral range, with potential for breakout above $376.89 or breakdown below $274.76.
Key Levels & Action Items
Critical Price Levels:
- Support at $325.82
- Resistance at $376.89
Breakout/Breakdown Levels:
- Above $376.89 could trigger a strong uptrend
- Below $274.76 could lead to a significant correction
Time-Sensitive Catalysts: Upcoming earnings release, product launches, and FDA approvals
Risk Management: Consider setting a stop-loss below $325.82 to manage potential downside risk.
This comprehensive analysis provides an objective assessment of BRKRP's technical momentum, news sentiment, and market context. The report highlights the stock's high volatility and potential risks, while also identifying opportunities for growth and breakout above $376.89.
BRKRP Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 234
Period: 252 trading days
High volatility - stock moves more than market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Scion Asset Management Hedge fund Michael Burry | $13.1M | #4 of 4 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BRKRP Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
BRKRP Insider Trading (Form 4)
Latest: 2026-06-16| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-16 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | Mixed | — | $38.48 | -$65.1K | EDGAR |
| 2026-05-19 | Thierry Bernard | Director | Award (A) | +2,886 | — | EDGAR | |
| 2026-05-18 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | Mixed | — | $33.05 | -$43.4K | EDGAR |
| 2026-04-16 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | Mixed | — | $31.05 | -$35.4K | EDGAR |
| 2026-03-16 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | Mixed | — | $28.82 | -$26.5K | EDGAR |
| 2026-02-18 | Bonnie H Anderson | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | Mixed | — | $29.57 | -$29.5K | EDGAR |
| 2026-02-18 | Hermann Fritz Requardt | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | Thomas Bures | Chief Accounting Officer | Tax (F) | −274 | $36.51 | -$10.0K | EDGAR |
| 2026-02-18 | Bob Rosenthal | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | Cynthia M Friend | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | Richard A Packer | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | Adelene Q Perkins | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | William A Linton | Director | Award (A) | +4,520 | — | EDGAR | |
| 2026-02-18 | John A Ornell | Director | Award (A) | +4,520 | — | EDGAR |
BRKRP Insider Holdings
13 insiders · @ $425.71| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Mark Munch | EXEC VP&PRES BRUKER NANO INC. | 128,443 | $54.68M | -$2.59M | 8 | 2026-06-16 |
| 2 | Richard A Packer | Director | 93,694 | $39.89M | -$243.2K | 2 | 2026-02-18 |
| 3 | William A Linton | Director | 63,243 | $26.92M | $0 | 1 | 2026-02-18 |
| 4 | John A Ornell | Director | 39,732 | $16.91M | -$243.1K | 2 | 2026-02-18 |
| 5 | Bob Rosenthal | Director | 38,781 | $16.51M | $0 | 1 | 2026-02-18 |
| 6 | Hermann Fritz Requardt | Director | 30,965 | $13.18M | $0 | 1 | 2026-02-18 |
| 7 | Adelene Q Perkins | Director | 29,144 | $12.41M | $0 | 1 | 2026-02-18 |
| 8 | Cynthia M Friend | Director | 22,536 | $9.59M | -$114.0K | 2 | 2026-02-18 |
| 9 | Bonnie H Anderson | Director | 17,847 | $7.60M | $0 | 1 | 2026-02-18 |
| 10 | Laura Francis | Director | 9,018 | $3.84M | $0 | 1 | 2026-02-18 |
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.